ROCKVILLE, Md., July 15,
2024 /PRNewswire/ -- Rise Therapeutics, a
clinical-stage biotechnology company developing novel oral
immunotherapeutic medicines, today announced that it has enrolled
its first patient in its R-5280 placebo controlled, blinded, Phase
1b type 1 diabetes clinical
trial.
Gary Fanger President and Chief
Executive Officer of Rise Therapeutics stated, "With our third drug
now in clinical development, we have the opportunity with R-5280 to
control another devastating disease using an oral immunotherapy
approach."
Type 1 diabetes is a chronic autoimmune condition where the
pancreas produces little to no insulin. Without enough insulin,
blood sugar levels can become dangerously high. Type 1 diabetes
typically develops in childhood or adolescence and patients require
lifelong insulin therapy to manage their blood sugar levels and
prevent complications. Approximately 1.6 million people in
the United States are affected by
type 1 diabetes, and around 40,000 people receive a new diagnosis
of type 1 diabetes in the U.S each year.
The Phase 1b clinical trial
(NCT06057454) is a placebo controlled, blinded clinical trial
designed to determine the clinical activity and safety of R-5280 in
new onset type 1 diabetes patients. The clinical study is being
conducted at multiple sites in the United
States. This repeat dose study in patients is meant to
determine if R-5280 can block the advancement of beta islet cell
destruction. The study will enroll 39 participants where clinical
activity will be evaluated by improvement in disease severity and
using a variety of key biomarkers.
About R-5280
R-5280 is an oral immunotherapy focused on controlling immune
pathways that lead to autoimmune disease. This product candidate
has been selectively designed to engage the immune system to
control inflammation by influencing immune cell differentiation and
inflammatory cytokine production that contribute to autoimmunity.
R-5280 has demonstrated improvement of type 1 diabetes symptoms in
a previous pilot clinical study.
About Rise Therapeutics
Rise Therapeutics is an emerging, privately held biotechnology
company located in Rockville,
Maryland, which leverages its expertise in synthetic biology
and immunological drug development to create novel cellular-based
immune therapies. With a strong emphasis on product development and
its internal clinical GMP manufacturing infrastructure, Rise is
focused on developing immunological-based biological medicines
using a unique and proprietary oral biologics delivery platform.
For more information, go to www.risetherapeutics.com.
Contact:
Media Relations
Email: hr@risetherapeutics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/first-type-1-diabetes-patient-enrolled-in-rise-therapeutics-latest-clinical-trial-302196848.html
SOURCE Rise Therapeutics